Contribution of post-transplantation therapy to sustained MRD negativity in multiple myeloma: a retrospective analysis
In conclusion, post-transplantation therapy improved PFS and contributed to sustained MRD-negativity in myeloma patients.PMID:38103160 | DOI:10.1007/s12185-023-03682-z (Source: International Journal of Hematology)
Source: International Journal of Hematology - December 16, 2023 Category: Hematology Authors: Kazuhito Suzuki Tadahiro Gunji Masaharu Kawashima Hideki Uryu Riku Nagao Mamiko Momoki Hiroki Yokoyama Hiroto Ishii Susumu Tanoue Takeshi Saito Kaichi Nishiwaki Shingo Yano Source Type: research
Cancers, Vol. 15, Pages 5846: Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study
idis
Evangelos Terpos
Newer methodologies are needed to assess the real-world comparative effectiveness of a “generation” of pharmaceutical innovation versus the prior standard of care. This chart review study aimed to first evaluate the cumulative clinical benefits of pharmaceutical innovation in everyday relapse/refractory multiple myeloma before analyzing findings in the context of respective real-world outcomes from the bortezomib/lenalidomide era. Study endpoints included the 52-week PFS rate in second and third line of therapy (LOT), mPFS-2 across the first and second LOT, the ORR, r...
Source: Cancers - December 14, 2023 Category: Cancer & Oncology Authors: Ioannis Petrakis Christos Kontogiorgis Evangelia Nena Sosana Delimpasi Natasa E. Loutsidi Emmanouil Spanoudakis Stergios Intzes Christina Misidou Marianthi Symeonidou Nikolaos Giannakoulas Theodoros C. Constantinidis Evangelos Terpos Tags: Article Source Type: research
Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease
Conclusions: We established a risk model incorporating extramedullary disease that provides accurate and individualized survival estimates for patients with NDMM.PMID:38086395 | DOI:10.1080/07853890.2023.2281657 (Source: Annals of Medicine)
Source: Annals of Medicine - December 12, 2023 Category: Internal Medicine Authors: Jing Wang Na Shen Xuxing Shen Run Zhang Yuanyuan Jin Jianyong Li Lijuan Chen Source Type: research
Recent trends in incidence, survival and treatment of multiple myeloma in Finland – a nationwide cohort study
This study aimed to determine the incidence and prevalence of multiple myeloma (MM) in Finland in 2015 –2019, to characterize adult patients newly diagnosed with MM, and to follow-up their overall survival (OS) and treatment patterns until the end of 2020. We sourced the data on inpatient and outpatient diagnoses, outpatient medication use, and date of death from comprehensive, nationwide registers . We identified 2037 incident patients with MM in 2015–2019. On average, the annual crude incidence was 8.8 and the age-standardized incidence (World Standard Population) was 3.3 per 100,000. The crude prevalence at the end ...
Source: Annals of Hematology - December 12, 2023 Category: Hematology Source Type: research
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
CONCLUSION: Frail patients treated with PVd demonstrated a higher ORR and a longer PFS and DoT vs. Vd, despite a higher frequency of grade ≥ 3 TEAEs leading to pomalidomide, bortezomib, and/or dexamethasone discontinuation. Therefore, PVd treatment may improve patient outcomes, regardless of frailty.PMID:38072743 | DOI:10.1016/j.clml.2023.10.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 10, 2023 Category: Cancer & Oncology Authors: Albert Oriol Meletios Dimopoulos Fredrik Schjesvold Meral Beksac Thierry Facon Sujith Dhanasiri Shien Guo Yutian Mu Kevin Hong Christian Gentili Monica Galli Munci Yagci Alessandra Larocca Paul Richardson Katja Weisel Source Type: research
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
CONCLUSION: Frail patients treated with PVd demonstrated a higher ORR and a longer PFS and DoT vs. Vd, despite a higher frequency of grade ≥ 3 TEAEs leading to pomalidomide, bortezomib, and/or dexamethasone discontinuation. Therefore, PVd treatment may improve patient outcomes, regardless of frailty.PMID:38072743 | DOI:10.1016/j.clml.2023.10.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 10, 2023 Category: Cancer & Oncology Authors: Albert Oriol Meletios Dimopoulos Fredrik Schjesvold Meral Beksac Thierry Facon Sujith Dhanasiri Shien Guo Yutian Mu Kevin Hong Christian Gentili Monica Galli Munci Yagci Alessandra Larocca Paul Richardson Katja Weisel Source Type: research
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
CONCLUSION: Frail patients treated with PVd demonstrated a higher ORR and a longer PFS and DoT vs. Vd, despite a higher frequency of grade ≥ 3 TEAEs leading to pomalidomide, bortezomib, and/or dexamethasone discontinuation. Therefore, PVd treatment may improve patient outcomes, regardless of frailty.PMID:38072743 | DOI:10.1016/j.clml.2023.10.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 10, 2023 Category: Cancer & Oncology Authors: Albert Oriol Meletios Dimopoulos Fredrik Schjesvold Meral Beksac Thierry Facon Sujith Dhanasiri Shien Guo Yutian Mu Kevin Hong Christian Gentili Monica Galli Munci Yagci Alessandra Larocca Paul Richardson Katja Weisel Source Type: research
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
CONCLUSION: Frail patients treated with PVd demonstrated a higher ORR and a longer PFS and DoT vs. Vd, despite a higher frequency of grade ≥ 3 TEAEs leading to pomalidomide, bortezomib, and/or dexamethasone discontinuation. Therefore, PVd treatment may improve patient outcomes, regardless of frailty.PMID:38072743 | DOI:10.1016/j.clml.2023.10.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 10, 2023 Category: Cancer & Oncology Authors: Albert Oriol Meletios Dimopoulos Fredrik Schjesvold Meral Beksac Thierry Facon Sujith Dhanasiri Shien Guo Yutian Mu Kevin Hong Christian Gentili Monica Galli Munci Yagci Alessandra Larocca Paul Richardson Katja Weisel Source Type: research
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
CONCLUSION: Frail patients treated with PVd demonstrated a higher ORR and a longer PFS and DoT vs. Vd, despite a higher frequency of grade ≥ 3 TEAEs leading to pomalidomide, bortezomib, and/or dexamethasone discontinuation. Therefore, PVd treatment may improve patient outcomes, regardless of frailty.PMID:38072743 | DOI:10.1016/j.clml.2023.10.009 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - December 10, 2023 Category: Cancer & Oncology Authors: Albert Oriol Meletios Dimopoulos Fredrik Schjesvold Meral Beksac Thierry Facon Sujith Dhanasiri Shien Guo Yutian Mu Kevin Hong Christian Gentili Monica Galli Munci Yagci Alessandra Larocca Paul Richardson Katja Weisel Source Type: research
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival
ConclusionThe prognostic significance for the number of immune markers is only seen in the PVd arm and none of these immune markers exhibit prognostic values in the Vd arm. This study demonstrates the importance of the immunomodulatory effects and the therapeutic benefit of adding pomalidomide to Vd treatment. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - December 4, 2023 Category: Cancer & Oncology Source Type: research
An Updated Comprehensive Pharmacovigilance Study of Drug-Induced Thrombocytopenia based on FDA Adverse Event Reporting System Data
This article is protected by copyright. All rights reserved.PMID:38041205 | DOI:10.1002/jcph.2389 (Source: The Journal of Clinical Pharmacology)
Source: The Journal of Clinical Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Li Kunyu Shi Shuping Su Chang Cao Yiyue Xiong Qinyu Zhang Ting Wu Bin Source Type: research
Drug-induced tumoral disease: A global pharmacovigilance database analysis
DISCUSSION: Our results show that the main pharmacological mechanisms are associated with ranitidine (link with levels of N-nitrosodimethylamine in ranitidine-based drugs), gene-activating drugs (pioglitazone: link with agonist effects on PPAR-γ gene activation), various pharmacological families with immunosuppressive effects (protein kinase inhibitors, immunomodulators, azathioprine, etc.), certain types of protein kinase inhibitors whose oncogenic mechanisms remain unclear (regorafenib, sorafenib, imatinib, ibrutinib, etc.), and hormone antagonists (tamoxifen, letrozole). Special monitoring of patients exposed to these ...
Source: Therapie - December 2, 2023 Category: Psychiatry & Psychology Authors: Yoann Zelmat Fabien Despas Source Type: research
An Updated Comprehensive Pharmacovigilance Study of Drug-Induced Thrombocytopenia based on FDA Adverse Event Reporting System Data
This article is protected by copyright. All rights reserved.PMID:38041205 | DOI:10.1002/jcph.2389 (Source: The Journal of Clinical Pharmacology)
Source: The Journal of Clinical Pharmacology - December 2, 2023 Category: Drugs & Pharmacology Authors: Li Kunyu Shi Shuping Su Chang Cao Yiyue Xiong Qinyu Zhang Ting Wu Bin Source Type: research
